| Abstrakt: |
Benign prostatic hypertrophy (BPH) is commonly treated medically, usually with an α1-adrenoceptor antagonist or a steroid 5-α-reductase inhibitor. Recent evidence from long-term clinical trials has shown that combined therapy with these two therapeutic classes is more effective than either agent alone in delaying disease progression. New strategies for the treatment of BPH are still in early stages of development, but some, such as the use of phosphodiesterase inhibitors, might lead to significant improvements in disease management. [Copyright &y& Elsevier] |
Full Text from ScienceDirect